Takeda, Daiichi Sankyo Prepared To Produce Own Flu Vaccines
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical and Daiichi Sankyo plan to produce their own flu vaccines, both seasonal and H1N1, according to sources
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.